Stockscreener 앱 받기
27.60
0.93%
-0.26
전일 마감가:
$27.86
열려 있는:
$27.33
하루 거래량:
1.07M
Relative Volume:
0.72
시가총액:
$2.18B
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-10.11
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
-7.29%
1개월 성능:
-16.21%
6개월 성능:
+103.54%
1년 성능:
+170.59%
1일 변동 폭
$27.33
$28.65
1주일 범위
$27.33
$32.21
52주 변동 폭
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
27.60 | 2.20B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
David Malcom Rodman Sells 14,055 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS officer sells $569k in stock - Investing.com
Mineralys Therapeutics Breaks Below 200-Day Moving AverageNotable for MLYS - Nasdaq
How strong is Mineralys Therapeutics Inc. stock balance sheetJuly 2025 EndofMonth & Long-Term Safe Return Strategies - mfd.ru
Mineralys Therapeutics launches $175M public offering - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
Is Mineralys Therapeutics Inc. a top pick in the sector2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Candriam S.C.A. - MarketBeat
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 60% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS) - MarketBeat
Panic Selling: How sensitive is Mineralys Therapeutics Inc to inflationJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Mineralys Therapeutics (MLYS) to Release Earnings on Wednesday - MarketBeat
Profit Review: How sensitive is Mineralys Therapeutics Inc to inflation2025 Momentum Check & Safe Entry Trade Reports - baoquankhu1.vn
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Finviz
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Uncovering a 53.98% Potential Upside in Biotech - DirectorsTalk Interviews
What is HC Wainwright's Forecast for MLYS FY2030 Earnings? - MarketBeat
Insider Trends: How sensitive is Mineralys Therapeutics Inc to inflationWeekly Trade Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Aug EndMonth: Will CMPS benefit from rate cutsJuly 2025 Pullbacks & AI Powered Market Entry Ideas - baoquankhu1.vn
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (MLYS) Movement - Stock Traders Daily
Mineralys Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
Relative Strength Alert For Mineralys Therapeutics - Nasdaq
Rodman sells Mineralys (MLYS) shares for $13,353 By Investing.com - Investing.com Nigeria
Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Fed Watch: What is Mineralys Therapeutics Incs revenue forecast2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Activity Recap: Is EKSO a potential multi baggerAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Are Mineralys Therapeutics’ (MLYS) Executive Stock Plans Aligned With Lorundrostat’s Emerging Investment Story? - Sahm
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock - MarketBeat
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Sell Signal: Is Mineralys Therapeutics Inc. part of any major index2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock By Investing.com - Investing.com Canada
Mineralys Therapeutics MLYS officer sells $277k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com
Mineralys Therapeutics MLYS officer sells $277k in stock - Investing.com
Buybacks Report: Will Mineralys Therapeutics Inc outperform tech stocksQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Patterns Watch: Whats Mineralys Therapeutics Incs historical returnJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Unveiling a 54% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):